Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
Cold and hot tumors: from molecular mechanisms to targeted therapy
B Wu, B Zhang, B Li, H Wu, M Jiang - Signal Transduction and Targeted …, 2024 - nature.com
Immunotherapy has made significant strides in cancer treatment, particularly through
immune checkpoint blockade (ICB), which has shown notable clinical benefits across …
immune checkpoint blockade (ICB), which has shown notable clinical benefits across …
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer …
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …
Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Therapy for stage IV non–small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3
Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …
drives frequent change in recommended clinical practice. Living guidelines are updated on …
New promises and challenges in the treatment of advanced non-small-cell lung cancer
Targeted therapies and immunotherapies have radically improved treatment for advanced
non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver …
non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver …
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung …
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged
overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or …
overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or …
[HTML][HTML] CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
Immune checkpoint blockade (ICB) with PD-1/PD-L1 inhibition has revolutionized the
treatment of non-small cell lung cancer (NSCLC). Durable responses, however, are …
treatment of non-small cell lung cancer (NSCLC). Durable responses, however, are …
Regulatory T cells in immune checkpoint blockade antitumor therapy
A Zhang, T Fan, Y Liu, G Yu, C Li, Z Jiang - Molecular Cancer, 2024 - Springer
Regulatory T cells (Tregs), an essential component of the human immune system, are a
heterogeneous group of T lymphocytes with the ability to suppress immune responses and …
heterogeneous group of T lymphocytes with the ability to suppress immune responses and …
Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of
patients with advanced non–small cell lung cancer without driver genetic alterations. Most of …
patients with advanced non–small cell lung cancer without driver genetic alterations. Most of …